Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
Fiche publication
Date publication
janvier 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr HUMBERT Philippe
Tous les auteurs :
Pierard GE, Aubin F, Humbert P
Lien Pubmed
Résumé
Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.
Référence
Dermatol Res Pract. 2012;2012:182157